Writing in JAMA, four former government officials warn that the Trump administration’s involvement in delaying the approval ...

Shares of Novavax Inc. NVAX rose 2.85% to $6.49 Tuesday, on what proved to be an all-around positive trading session for the ...

Retail investor chatter around vaccine makers Novavax, Moderna, and Pfizer rose on Wednesday, ahead of a closely watched CDC ...

Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Novavax, Inc. faces profitability challenges despite a promising tech platform, with uncertain revenue streams. Click for my ...

Novavax Inc. closed 64.57% short of its 52-week high of $17.81, which the company achieved on July 26th.

For many, Novavax is #1 – the one and only COVID vaccine they would consider. This enthusiasm for Novavax isn’t new. As far back as 2022, news reports described a kind of Novavax fan club ...

Novavax (NVAX) concluded the recent trading session at $6.41, signifying a +1.75% move from its prior day's close.

Novavax's combo and standalone flu vaccines showed strong immune responses and good safety in a Phase 3 trial of adults 65 and older.

Novavax's experimental COVID-19-influenza combination and standalone influenza vaccines generated a strong immune response in ...

Novavax was authorized by the FDA for use in adults and children 12 and older, so younger kids can't get this vaccine. But for most adults, which COVID vaccine you should choose depends on your ...